Bone turnover markers in patients with osteogenesis imperfecta.

[Guest guest]

Bone. 2004 Jun;34(6):1013-6.  

Bone turnover markers in patients with osteogenesis imperfecta.

Braga V, Gatti D, Rossini M, Colapietro F, Battaglia E, Viapiana O, Adami S.

Rheumatology Unit, University of Verona, Valeggio S/M, Italy.

Osteogenesis imperfecta (OI) is a heterologous group of rare inherited bone

disorders resulting from defect in collagen synthesis or function. In

previous studies, bone turnover has been found either increased or

low-normal. These contradictory results might result from the study

population made of children with prior recent fractures. We measured serum

total and bone alkaline phosphatase (total and bone AP) serum osteocalcin

(sOC), serum type I collagen C-telopeptide breakdown products (sCTX),

urinary free-deoxypyridinoline (ufDPD), and urinary cross-linked

N-telopeptides of type I collagen (uNTX) in 39 male and 38 premenopausal

patients with different types of OI aged between 18 and 51 years who had not

experienced new clinical fracture during 12 months preceding the laboratory

assessment. The study also includes a control group of 29 men and 26 women

matched for age and gender. Most bone markers were 50-200% higher in

patients than in controls. Only sCTX was comparable to that found in

controls. From a sub-analysis of the data, a trend for higher bone

resorption markers was observed for any OI type, but patients with OI type

III and IV had significantly higher values in ufDPD and uNTX than patients

with type I OI, and their sOC levels were not significantly higher than in

controls. These results provide a strong rational for the use of

anti-resorbing agent in OI.

PMID: 15193547 [PubMed - in process]